Global Cystic Fibrosis Therapeutics Industry to reach USD XX billion by 2025.
Global Cystic Fibrosis Therapeutics Industry valued approximately USD XX billion in 2017 is anticipated to grow with a healthy growth rate of more than XX% over the forecast period 2019-2025. The major driving factor of global cystic fibrosis therapeutics Industry are rising prevalence of cystic fibrosis, rising awareness about cystic fibrosis therapy, technological advancement and high rate of Research & Development initiatives. The growing strategic collaboration is one of the key trends contributing towards the growth of the cystic fibrosis (CF) therapeutics Industry. The major restraining factors of the global cystic fibrosis therapeutics Industry are high cost related to the treatment, drug discontinuation and increase in complexity of disease. In addition, patent expiries from many companies and introduction of generic drugs is expected to restrain the growth of cystic fibrosis therapeutics Industry. The Cystic Fibrosis Therapeutics Industry is on the surging trend considering the global scenario. The Cystic fibrosis refers to an inherited disease which impacts the secretory glands of an individualâ€™s body such as Pancreas, lungs, liver and intestines. Cystic fibrosis transmembrane conductance regulator (CFTR) is synthesized in the rough endoplasmic reticulum (RER) followed by glycosylation in the Golgi apparatus and performing the function of a Cl- channel, and regulator of other ion channels when located in the plasma membrane. Cystic fibrosis leads to abnormal secretions that lead to mucus buildup which result in no proper working of an affected organ. Treatment of cystic fibrosis includes a physical therapy, which helps in loosening of mucus and use of medications and enzymes to fight against infections in an organ. Cystic fibrosis is caused due to mutation in gene that is required for protein CFTR.
The regional analysis of Global Cystic Fibrosis Therapeutics Industry is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America accounted leading share of total generating revenue in 2017 across the globe due to large number of aging population and high technological awareness and advancement. Asia-Pacific region region is also anticipated to exhibit higher growth rate / CAGR over the forecast period 2019-2025. China and India are expected to be the fastest growing cystic fibrosis Industrys in Asia-Pacific due to emerging countries are large pool of patients, rising government funding and increasing Research & Development investment.
The objective of the study is to define Industry sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the Industry. Additionally, the report shall also incorporate available opportunities in micro Industrys for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.
Cystic Fibrosis Therapeutics Industry Share and Size by 2019-2025
Cystic Fibrosis Therapeutics Market Segmentation:
* Pancreatic Enzyme Supplements
* CFTR Modulators
By Route of administration:
* Oral Drugs
* Inhaled Drugs
* North America
- Rest of Europe
- Rest of Asia-Pacific
- Latin America
- Middle East & Africa
Major Market Players in Cystic Fibrosis Therapeutics Market are as follows:
F. Hoffmann-La Roche Ltd.
Vertex Pharmaceuticals Inc.